DAY 2 - Friday, 12 March 2021
Session 5: Mucociliary Disorders and TB
Chair: Ibrahim A. Janahi – Qatar
14:00 – 14:25 | Cystic Fibrosis; The Year In Review
Asma Al Nuaimi – UAE
14:25 – 14:50 | Primary Ciliary Dyskinesia: Current Update
Claire Hogg – UK
14:50 – 15:15 | Current Updates on Tuberculosis
Amr Albanna – KSA
15:15 – 15:25 BREAK
Session 6: Interstitial Lung Disease
Chair: Nuha Alrajhi – KSA
15:25 – 15:50 | Transbronchial Cryobiopsy in ILDs
Felix Herth – Germany
15:50 – 16:15 | Progressive Non-IPF ILD: Clinical Implication
Rahmah Alsilmi – KSA
16:15 – 16:40 | Antifibrotic Therapies in IPF and Non-IPF ILD
Steven Nathan – USA
16:40 – 17:05 | Updates on Interstitial Lung Disease Management Boehringer Ingelheim
Sami Al Yami – USA
17:05 – 17:15 BREAK
Session 7: Severe Asthma – I
Chair: Bassam Mahboub – UAE
17:15 – 17:40 | Navigating Through the Complexities of Asthma Molecular Soup
Qutayba Hamid – UAE
17:40 – 18:05 | Microbiome-Immune Interactions in Adult Asthma
James Beck – USA
18:05 – 18:30 | Precision Medicine in Severe Asthma; Application of “Omics” Technologies
Juan C. Celedón – USA
18:30 – 18:55 | Biologic Therapies in Severe Asthma
Michael Wechsler – USA
18:55 – 19:20 | Treatments for Severe Asthma beyond T2 Inflammation
Kian Fan Chung – UK
19:20 – 19:30 BREAK
Session 8: Severe Asthma – II
Chair: Rabea Khouqeer – KSA
19:30 – 19:55 | Markers of Type 2 Asthma and there Role in Severe Asthma Sanofi
Ashraf Alzaabi – UAE
19:55 – 20:20 | Real World Evidence in Severe Asthma GSK
Emilio Pizzichini – Brazil
20:20 – 20:45 | IgE it, are we close to Precision Medicine? Novartis
Bassam Mahboub – UAE
Chair: Riyad Allehebi – KSA
20:50 – 21:15 | The Role of Eosinophilic Immune Dysfunction in Severe EOS Asthma
Adeeb Balkhi – KSA
21:15 – 21:45 | Biologics: Are they Capable of Leading to Remission?
Joseph Diaz – USA
21:45 – 21:50 | Q&A Panel Discussion & Closing
Riyad Allehebi – KSA